• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Concord Biotech: Stock Market’s New Biotech entrant ready with IPO
  • National Research Foundation (NRF): facing support and resistance from scientific communities! Why?
  • Biodiversity- preserve or perish
  • Dr Rajesh Gokhale assumes charge as Secretary of Department of Science and Technology
  • Advancing allergy detection and management in India: A pathway to improved health
  • Gujarat govt signs MOUs with 15 companies for ₹2000 cr in a single day
  • Pune biotech firm announces cheaper drug for colorectal cancer
  • Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Processors
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    May 22, 2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»BioResearch - Academic»Are too many Phase III cancer clinical trials set up to fail?

Are too many Phase III cancer clinical trials set up to fail?

0
By Biotech Express on September 23, 2021 BioResearch - Academic, Biotech News

New research in the September 2021 issue of JNCCN — Journal of the National Comprehensive Cancer Network finds that more than 80% of therapies tested in Phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival. The researchers analyzed 362 industry-sponsored Phase III randomized trials in oncology from 2008 to 2017, and found that 87% were either false-positive or true-negative for meeting overall survival goals. More than half of the initially reported positive trials were found to be false-positive (58.4%) for overall survival, while the overwhelming majority of negative results were determined to be true-negative (with only 0.9% false-negative).

Dr. Shen continued: “Our study shows that reducing false positive errors by imposing more stringent statistical threshold in Phase III trials is not likely to be practically feasible.

A better strategy is to rethink the process that leads to the decision of moving a new therapy to Phase III testing to begin with. More research is needed in this regard.””Our study highlights the need to more efficiently identify which new therapies merit Phase III testing,” said lead researcher Changyu Shen, PhD, Associate Professor at Harvard Medical School at the time this study was conducted.

“In order to sustain the rate of innovation in cancer therapeutics and ensure that our patients have access to effective yet affordable therapies, the clinical trial pipeline in oncology must be efficient and accurate. Our work shows that in the past ten years, this has not been the case.”

Most of the trials in this novel study focused on lung, breast, gastrointestinal, and hematologic cancers; trials with fewer than 100 participants were excluded, meaning rare cancer types were less likely to be included. The Phase III trials were predominately two-arm studies of an interventional regimen compared with a control treatment.

“This paper shows that a lot of drugs with ‘positive’ Phase III trials may have a smaller ultimate benefit than was expected, and that changing the threshold for statistical significance is not a quick fix,” said Elizabeth A. Handorf, PhD, Associate Research Professor, Fox Chase Cancer Center, who was not involved in this research. “I think it highlights the need for more efficient study designs, like adaptive trials, and clear definitions of what makes an effect clinically meaningful.”

Journal Reference: Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement. Journal of the National Comprehensive Cancer Network, 2021; 19 (9): 1072 DOI: 10.6004/jnccn.2020.7690

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Concord Biotech: Stock Market’s New Biotech entrant ready with IPO

Pune biotech firm announces cheaper drug for colorectal cancer

Indian scientist made First Marwari horse foal through Embryo transfer technology

Leave A Reply Cancel Reply

Current Issue – July 2023
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Concord Biotech: Stock Market’s New Biotech entrant ready with IPO July 31, 2023
  • National Research Foundation (NRF): facing support and resistance from scientific communities! Why? July 25, 2023
  • Biodiversity- preserve or perish July 24, 2023
  • Dr Rajesh Gokhale assumes charge as Secretary of Department of Science and Technology July 23, 2023
  • Advancing allergy detection and management in India: A pathway to improved health July 23, 2023
  • Gujarat govt signs MOUs with 15 companies for ₹2000 cr in a single day July 22, 2023
  • Pune biotech firm announces cheaper drug for colorectal cancer July 21, 2023
  • Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Processors July 20, 2023
  • BMJ Open retracted a diabetes paper because it was funded by tobacco company July 19, 2023
  • Indian scientist made First Marwari horse foal through Embryo transfer technology July 12, 2023
  • Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society May 22, 2023
  • FABA holds Conference on Antimicrobial Resistance Stewardship Series May 22, 2023
  • COVID no longer a global health emergency, WHO says May 18, 2023
  • Chemist in India loses seven papers of biology, blames outsourcing of images May 17, 2023
  • Indian Research scholars express frustration over DST’s tweet, plan stir May 16, 2023
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.